Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Seeking Alpha

17 Jun 2026, 09:52 UTC · 3h ago

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Read original · https://seekingalpha.com/article/4915476-opus-genetics-inc-ird-discusses-early-stage-gene-therapy-programs-and-clinical-strategies-for

Free · No account

Track these names every morning.

Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.

We’ll watch

#biotech#clinical_trials#gene_therapy#healthcare

Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.

Free forever · one email a day, max · unsubscribe in one click.How it works

How the impact breaks down

Where the story's weight lands

Impact by category

Sector Rotation+0.200

Biggest drivers

Healthcare+0.200

6 related stories

Zacks Investment Research
1h ago
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)
- biotech
- healthcare
Read

Opus Genetics, Inc. (IRD) Discusses Ea… | NewsImpactScreener

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Track these names every morning.

Impact by category

Biggest drivers

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Track these names every morning.

Impact by category

Biggest drivers

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Most positively impacted

Most negatively impacted

AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash

Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026

bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript

ROSEN, NATIONAL TRIAL LAWYERS, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Track these names every morning.

Impact by category

Biggest drivers

Next reads from the same story arc

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Opus Genetics, Inc. (IRD) Discusses Early-Stage Gene Therapy Programs and Clinical Strategies for Inherited Retinal Diseases Transcript

Track these names every morning.

Impact by category

Biggest drivers

Next reads from the same story arc

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised)

Most positively impacted

Most negatively impacted

AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its Cash

Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026

bioAffinity Technologies, Inc. (BIAF) Discusses Noninvasive Testing and Risk Stratification for Indeterminate Lung Nodules Transcript

ROSEN, NATIONAL TRIAL LAWYERS, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GRAL

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study